183 related articles for article (PubMed ID: 30367922)
1. Synthetic cannabinoids nano-micelles for the management of triple negative breast cancer.
Greish K; Mathur A; Al Zahrani R; Elkaissi S; Al Jishi M; Nazzal O; Taha S; Pittalà V; Taurin S
J Control Release; 2018 Dec; 291():184-195. PubMed ID: 30367922
[TBL] [Abstract][Full Text] [Related]
2. The Use of Styrene Maleic Acid Nanomicelles Encapsulating the Synthetic Cannabinoid Analog WIN55,212-2 for the Treatment of Cancer.
Xian S; Parayath NN; Nehoff H; Giles NM; Greish K
Anticancer Res; 2015 Sep; 35(9):4707-12. PubMed ID: 26254360
[TBL] [Abstract][Full Text] [Related]
3. Effect of styrene maleic acid WIN55,212-2 micelles on neuropathic pain in a rat model.
Linsell O; Brownjohn PW; Nehoff H; Greish K; Ashton JC
J Drug Target; 2015 May; 23(4):353-9. PubMed ID: 25541465
[TBL] [Abstract][Full Text] [Related]
4. Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro.
Slivicki RA; Xu Z; Mali SS; Hohmann AG
Pharmacol Res; 2019 Apr; 142():267-282. PubMed ID: 30739035
[TBL] [Abstract][Full Text] [Related]
5. R-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: partial involvement of the CB(2) receptor.
Sánchez AJ; González-Pérez P; Galve-Roperh I; García-Merino A
Biochem Pharmacol; 2006 Dec; 72(12):1697-706. PubMed ID: 17007821
[TBL] [Abstract][Full Text] [Related]
6. Blood, adipose tissue and brain levels of the cannabinoid ligands WIN-55,212 and SR-141716A after their intraperitoneal injection in mice: compound-specific and area-specific distribution within the brain.
Barna I; Till I; Haller J
Eur Neuropsychopharmacol; 2009 Aug; 19(8):533-41. PubMed ID: 19303746
[TBL] [Abstract][Full Text] [Related]
7. Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC).
Godugu C; Doddapaneni R; Singh M
Colloids Surf B Biointerfaces; 2017 May; 153():208-219. PubMed ID: 28249200
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.
Yuan SJ; Xu YH; Wang C; An HC; Xu HZ; Li K; Komatsu N; Zhao L; Chen X
J Nanobiotechnology; 2019 Oct; 17(1):110. PubMed ID: 31623629
[TBL] [Abstract][Full Text] [Related]
9. Involvement of spinal cannabinoid receptors in the antipruritic effects of WIN 55,212-2, a cannabinoid receptor agonist.
Bilir KA; Anli G; Ozkan E; Gunduz O; Ulugol A
Clin Exp Dermatol; 2018 Jul; 43(5):553-558. PubMed ID: 29424035
[TBL] [Abstract][Full Text] [Related]
10. Selective Targeting of Breast Cancer by Tafuramycin A Using SMA-Nanoassemblies.
El-Deeb IM; Pittala V; Eltayeb D; Greish K
Molecules; 2021 Jun; 26(12):. PubMed ID: 34207832
[TBL] [Abstract][Full Text] [Related]
11. Inverse relationship of cannabimimetic (R+)WIN 55, 212 on behavior and seizure threshold during the juvenile period.
Rudenko V; Rafiuddin A; Leheste JR; Friedman LK
Pharmacol Biochem Behav; 2012 Jan; 100(3):474-84. PubMed ID: 22019959
[TBL] [Abstract][Full Text] [Related]
12. Ovatodiolide sensitizes aggressive breast cancer cells to doxorubicin, eliminates their cancer stem cell-like phenotype, and reduces doxorubicin-associated toxicity.
Bamodu OA; Huang WC; Tzeng DT; Wu A; Wang LS; Yeh CT; Chao TY
Cancer Lett; 2015 Aug; 364(2):125-34. PubMed ID: 25976769
[TBL] [Abstract][Full Text] [Related]
13. Transdermal delivery of the synthetic cannabinoid WIN 55,212-2: in vitro/in vivo correlation.
Valiveti S; Hammell DC; Earles DC; Stinchcomb AL
Pharm Res; 2004 Jul; 21(7):1137-45. PubMed ID: 15290852
[TBL] [Abstract][Full Text] [Related]
14. Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain.
Costa B; Colleoni M; Conti S; Trovato AE; Bianchi M; Sotgiu ML; Giagnoni G
Br J Pharmacol; 2004 Jan; 141(1):4-8. PubMed ID: 14662732
[TBL] [Abstract][Full Text] [Related]
15. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
[TBL] [Abstract][Full Text] [Related]
16. Nitric oxide-releasing nanoparticles improve doxorubicin anticancer activity.
Alimoradi H; Greish K; Barzegar-Fallah A; Alshaibani L; Pittalà V
Int J Nanomedicine; 2018; 13():7771-7787. PubMed ID: 30538458
[TBL] [Abstract][Full Text] [Related]
17. Toxicokinetics of new psychoactive substances: plasma protein binding, metabolic stability, and human phase I metabolism of the synthetic cannabinoid WIN 55,212-2 studied using in vitro tools and LC-HR-MS/MS.
Mardal M; Gracia-Lor E; Leibnitz S; Castiglioni S; Meyer MR
Drug Test Anal; 2016 Oct; 8(10):1039-1048. PubMed ID: 26810883
[TBL] [Abstract][Full Text] [Related]
18. Synergistic Effect of SH003 and Doxorubicin in Triple-negative Breast Cancer.
Woo SM; Kim AJ; Choi YK; Shin YC; Cho SG; Ko SG
Phytother Res; 2016 Nov; 30(11):1817-1823. PubMed ID: 27476488
[TBL] [Abstract][Full Text] [Related]
19. Antineoplastic effect of WIN 55,212-2, a cannabinoid agonist, in a murine xenograft model of gastric cancer.
Oh JH; Lee JY; Baeg MK; Han KH; Choi MG; Park JM
Chemotherapy; 2013; 59(3):200-6. PubMed ID: 24335109
[TBL] [Abstract][Full Text] [Related]
20. Characterization of cannabinoid-induced relief of neuropathic pain in rat models of type 1 and type 2 diabetes.
Vera G; López-Miranda V; Herradón E; Martín MI; Abalo R
Pharmacol Biochem Behav; 2012 Aug; 102(2):335-43. PubMed ID: 22609797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
